WO2024023745 - TREATMENT FOR ACUTE ORGAN INJURY USING CD39, RECOMBINANT CD39
National phase entry:
Publication Number
WO/2024/023745
Publication Date
01.02.2024
International Application No.
PCT/IB2023/057612
International Filing Date
27.07.2023
Title **
[English]
TREATMENT FOR ACUTE ORGAN INJURY USING CD39, RECOMBINANT CD39
[French]
TRAITEMENT D'UNE LÉSION ORGANIQUE AIGUË À L'AIDE DE CD39, DE CD39 RECOMBINANT
Applicants **
NOVARTIS AG
Inventors
CALONDER, Claudio
IBRAM, Ghionul
JUNGE, Guido
ROWLAND, Matthew James
TAUBERT, Max Philipp
WARNCKE, Max
WEISS, Hermann Markus
ZHOU, Yinong
Priority Data
63/369,839
29.07.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2276 | |
| EPO | Filing, Examination, Granting | 11204 | |
| Japan | Filing, Examination, Granting | 2331 | |
| South Korea | Filing, Examination, Granting | 2360 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,911
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention pertains to the use for treating organ injury, in particular acute organ injury, such as acute kidney injury (AKI) using CD39, human recombinant CD39 and variants thereof.[French]
La présente invention concerne l'utilisation pour traiter une lésion organique, en particulier une lésion organique aiguë, telle qu'une lésion rénale aiguë (AKI), à l'aide de CD39, de CD39 recombinant humain et de variants de celui-ci.